A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Cutaneous Sarcoidosis

In brief

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

Key facts

Study ID

NCT06978725

Run by

Priovant Therapeutics, Inc.

People needed

28

Starts

2025-04-09

Expected to finish

2026-12-01

Last updated by the study team

2025-05-18

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults subjects (18-74)
• Cutaneous sarcoidosis with characteristic skin biopsy histology
• A CSAMI activity score ≥ 10
• Weight > 40 kg to < 130 kg with BMI < 40 kg/m2 .

You may not qualify if…

• History of
• Lymphoproliferative disorder
• Active malignancy;
• History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix).
• High risk of thrombosis or cardiovascular disease
• High risk of herpes zoster
• Active or recent infection

Where it is running

• Clinical Trial Site — San Francisco, California, United States (enrolling)
• Clinical Trial Site — Durham, North Carolina, United States (enrolling)
• Clinical Trial Site — Philadelphia, Pennsylvania, United States (enrolling)
• Clinical Trial Site — Madison, Wisconsin, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.